Analyst Reco. Q32 Bio Inc.

Equities

QTTB

US7469641051

Market Closed - Nasdaq Other stock markets 01:30:00 01/05/2024 am IST			5-day change	1st Jan Change
27.4 ^USD	-5.65%		+7.45%	+150.37%

11/04	Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target	MT
03/04	Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target	11/04	MT
Piper Sandler Initiates Q32 Bio With Overweight Rating, $45 Price Target	02/04	MT
Baird Downgrades Homology Medicines to Neutral From Outperform, Adjusts Price Target to $1.50 From $9	28/23/28	MT
Chardan Cuts Price Target on Homology Medicines to $7 From $8, Maintains Buy Rating	12/23/12	MT
Chardan Lowers Price Target on Homology Medicines to $8 From $10, Keeps Buy Rating	17/22/17	MT
RBC Cuts Price Target on Homology Medicines to $3 From $4, Maintains Sector Perform, Speculative Risk	11/22/11	MT
Baird Adjusts Price Target on Homology Medicines to $9 From $10, Keeps Outperform Rating	31/22/31	MT
Chardan Lowers Homology Medicines' Price Target to $10 From $14, Maintains Buy Rating	16/22/16	MT
BTIG Adjusts Price Target on Homology Medicines to $12 From $29, Reiterates Buy Rating	16/22/16	MT
Chardan Trims Homology Medicines' Price Target to $14 From $15, Reiterates Buy Rating	17/22/17	MT
Credit Suisse Initiates Homology Medicines at Neutral, $2.70 Price Target	28/22/28	MT
Canaccord Genuity Adjusts Homology Medicines' Price Target to $7 From $19, Maintains Buy Rating	06/22/06	MT
HC Wainwright Adjusts Homology Medicines' Price Target to $20 from $30, Keeps Buy Rating	28/22/28	MT
BofA Securities Adjusts Homology Medicines' Price Target to $9 from $25, Keeps Buy Rating	22/22/22	MT
Homology Medicines Shares Dive 30% to 52-Week Low After Trial Hold, Analysts Cuts	22/22/22	DJ
Chardan Lowers Homology Medicines PT to $15 From $25 After FDA's Clinical Hold on PheNIX Based on Clinical Observations, Maintains Buy Rating	22/22/22	MT
Oppenheimer Downgrades Homology Medicines to Perform From Outperform, Removes $22 Price Target	22/22/22	MT
Homology Medicines Shares Drop 27% After Gene Therapy Trial Halted By FDA	22/22/22	DJ
RBC Downgrades Homology Medicines to Sector Perform From Outperform, Price Target Slashed to $4 From $30, Shares Fall 25%	22/22/22	MT
Baird Adjusts Homology Medicines' Price Target to $10 From $16, Maintains Outperform Rating	22/22/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Q32 Bio Inc.

Equities

QTTB

US7469641051

Analyst Reco.

Filters